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Several factors are involved in the regulation of growth and differentiation of
B cells (reviewed in 1) . In fact, B cell stimulatory factor 2 (BSF-2),' which has
recently been cloned (2), is a distinct cytokine of 21 kD that acts on activated
normal human B cells as well as EBV-transformed B-lymphoblastoid cell lines to
induce immunoglobulin secretion (3, 4) . The study with the antipeptide antibody
specific to BSF-2 demonstrated that several tumor cells, including cardiac myxo-
mas, produce BSF-2, and patients with such tumors show hypergammaglobuli-
nemia and autoantibody production (5) . From these earlier investigations it was
suggested that BSF-2 has an important role in the regulation of antibody
production .
Recent reports have indicated identity between BSF-2 and other cytokines
known as interferon 02 (IFN -N2) and hybridoma plasmacytoma growth factor
(HPGF) (6, 7) . Another identical molecule is also reported as a 26 kD protein
(8) that is expressed in human fibroblast by poly (IC) in the presence of
cycloheximide (9) or (IL-1) (10) . These facts suggest that BSF-2 has an important
role not only in the immunoglobulin production of B cells but also in the
regulation of growth and differentiation of several other types of cells . The
recombinant BSF-2 had no detectable antiviral activity2 (11), and it has been
proposed that it be called IL-6 (11) .
However, no information is available as to the presence of specific BSF-2
receptors (BSF-2-R) mediating the physiological effects . The availability of highly
purified BSF-2 produced in Escherichia coli by recombinant DNA techniques
enabled us to study the presence and the properties ofBSF-2-R . We report here
in this study the number and distribution of BSF-2-R . Our findings indicate that
BSF-2-R are widely distributed in several tissues and cell lines . In contrast to
BSF-1-R, which are found on resting B cells (12), our observations indicate that
normal B cells express BSF-2-R only after activation .
'Abbreviations used in this paper:
￿
AET, S-(2-aminoethyl)isothiouronium bromide; BSF-2, B cell
stimulatory factor 2; G-CSF, granulocyte colony-stimulating factor ; MNC, mononuclear cell ; SAC,
Staphyloccocus aureus Cowan 1 .
2 Hirano, T., T. Matsuda, K. Hosoi, A. Okano, H. Matsui, andT. Kishimoto. B cell stimulatory
factor 2 (BSF-2/IFN-ß2) does not belong to the family of interferons . Manuscript submitted for
publication .
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Materials and Methods
Lymphokines.
￿
Recombinant BSF-2 was prepared by expressing a cDNA for BSF-2 (2)
in E. coli, followed by further purification. Specific activity was determined as 3.6 X 109
U/g by using the BSF-2-responsive human B lymphoblastoid cell line, SKW6-CL4 (4).
Human IFN-ß and IFN-f were kind gifts from Tory, Co., Ltd. (Tokyo, Japan) and
possessed specific activities of 1 .3 X 10 ' and 5.9 X 10 U/g, respectively. Recombinant
human IL-1,8 and IL-2 were supplied b7 Otsuka pharmaceutical Co., Ltd. (Tokushima,
Japan), at specific activities of 2.0 X 10' and 5.0 X 10'° U/g, respectively. Recombinant
human granulocyte colony-stimulating factor (G-CSF) with a specific activity of 2.5-10 X
10'° U/g was generously
￿
rovided by Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan).
Iodination ofBSF-2.
￿
' 1-BSF-2 was prepared as described by Bolton and Hunter (13)
with some modifications. 5 wg of recombinant BSF-2 dissolved in 10 Al of 0.1 M borate
buffer, pH 8.5, was added to 500 ACi ofdry Bolton and Hunter reagent (2,000 Ci/mmol ;
Amersham Corp., Arlington Heights, IL) and the reaction mixture was agitated for 15
min on ice. The reaction was stopped by adding 0.5 ml of 0 .2 M glycine in 0.1 M borate
buffer, pH 8 .5, with further mixing for 5 min on ice . '251-labeled BSF-2 was separated
from `2 I-labeled products of low molecular mass using a gel filtration column (PD-10;
Pharmacia Fine Chemicals, Piscataway, NJ). "'I-BSF-2 was diluted with RPM] 1640, 25
mM Hepes, pH 7 .2, 3 mg/ml BSA, 100 pg/ml streptomycin, and 100 U/ml penicillin
(binding medium), filter sterilized, and stored at 4°C. Purity and molecular mass of
'25I-
BSF-2 was examined by SDS-PAGE on a slab gel (10-20% continuous gradient of
acrylamide) followed by autoradiography.
Binding Assay.
￿
Usual binding assay was performed as follows: cells for assay were
washed twice and incubated in binding medium for at least 10 min at 37°C. 106 cells
were mixed with 1251-BSF-2 with or without a 200-fold excess of unlabeled BSF-2 in a
final volume of 70 Al of binding medium, and incubated on ice for 150 min with occasional
agitation every 10-15 min. At the end of incubation, the reaction mixture was layered
on a 300-j,l cushion of FCS in a 400-Al polypropylene tube and centrifuged at 9,000 rpm
for 90 s. The tube was cut just above the cell pellet, and the cell-associated radioactivity
was measured in a Beckman Gamma 9000 (Beckman Instruments, Fullerton, CA). The
specific binding was calculated after subtracting the count of the samples with 200-fold
excess unlabeled BSF-2 (nonspecific bound count) .
Determination of Specific Radioactivity of '25I-BSF-2.
￿
Maximal binding capacity was
measured according to a described method (14). Briefly, varjmg numbers of EBV-
transformed B-LCL, LESS cells were mixed with 9,300 cpm Of 12 I-BSF-2 with or without
a 200-fold excess of unlabeled BSF-2 in a final volume of 70 Al of binding medium .
Reaction mixtures were incubated on ice for 150 min with frequent agitation every 10-
15 min . Specific binding was calculated as indicated above and data were plotted as
reciprocal radioactivity specifically bound versus reciprocal cell number. From the ordi-
nate intercept of a regression line of the plots, maximal binding capacity at infinite cell
number was determined.
Self-displacement analysis was9erformed according to Calvo et al. (14). 106 CESS cells
were mixed with 9,300 cpm of ' I-BSF-2 and increasing amounts of unlabeled BSF-2 or
"'I-BSF-2 were added in a total volume of 70 Al of binding medium. At the end of 150
min of incubation on ice, the cells were separated by centrifugation on FCS, and cell-
associated radioactivity was measured. Data were transformed into a bound/free ratio
and plotted against loglo(amount of unlabeled BSF-2 [in nanograms]) or loglp(amount of
"'I-BSF-2 [counts per minute]). Two regression lines were drawn and the specific
radioactivity was determined as the amount of radioactivity divided by the amount of
unlabeled BSF-2 added to obtain the same bound/free ratio.
Human Cell Lines.
￿
SK-MG-4 and SK-N-MC were kindly provided by Dr. R. Ueda,
Aichi Cancer Institute, Nagoya, Japan . Daudi, HSB, CEM, Jurkat, and U937 were
provided by Dr. P. Ralph, Memorial Sloan-Kettering Cancer Center, New York. Reh and
KM-3 were provided by K. Kikuchi, Sapporo Medical College, Sapporo, Japan. HL60 and
U373 were obtained from the American Type Culture Collection, Rockville, MD. BL41
and BL41/45 were from Dr. G. Klein (Karolinska Institute). Louckes and EBNA2-TAGA ET AL .
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FIGURE 1 . Autoradiograph of ' 2-1I-BSF-2 analyzed by SDS-PAGE .
Recombinant BSF-2 was iodinated and an aliquot was applied on
polyacrylamide gel with a continuous gradient of 10-20% acrylamide .
The molecular mass (kD) of protein standards are also indicated .
transfected Louckes cells were from Dr. E. Kieff (University of Chicago, Chicago, IL) .
EBV-transformed B cell lines SKW6-CL4, LCL13, and LCL14 were described elsewhere
(2, 15). All human cell lines except U373 were maintained in RPMI 1640, 10% FCS, 5 X
10'5M 2-ME, 100 U/ml penicillin, 100 pg/ml streptomycin . U373 was cultured in MEM,
10% FCS, 100 pg/ml sodium pyruvate, and nonessential amino acid mixture (Gibco,
Grand Island, NY). All were cultured at 37°C, in humidified 5% C02 in air .
NormalHuman TandB Cells.
￿
HumanTandBcellswere prepared as follows. Tonsillar
cells were dispersed on a plastic dish and mononuclear cells (MNC) were isolated by
centrifugation on Ficoll-paque (Pharmacia Fine Chemicals). T cells were prepared from
MNC by two sequential rosettings with S-(2-aminoethyl)isothiouronium bromide (AET)-
treated SRBC . B cells were isolated from MNC by AET-treated SRBC-rosetting twice,
and rosette-negative cells were further treated with anti-CD2 (kindly provided by Dr. E.
L. Clark) and rabbit complement to eliminate possible contaminatingT cells . The purity
ofT and B cells were examined by FACS analysis . T and B cells were cultured in the
same medium described above for most of the cell lines at a density of 2 X 106/ml . PWM
(Sigma Chemical Co ., St . Louis, MO), 2.5 wg/ml final concentration ; PHA (Sigma
Chemical Co .), 0.1% wt/vol, final concentration ; and Staphylococcus aureus Cowan I (SAC)
from Bethesda Research Laboratories,Gaithersburg, MD, 0.003% (vol/vol), final concen-
tration, were used as stimulants . Size fractionation of B and T cells was performed by
Percoll (Pharmacia Fine Chemicals) discontinuous gradient centrifugation . Large cells
were separated from the interface between 40 and 50% Percoll, and small cellswere from
the interface between 55 and 70% after centrifugation at 3,500 rpm for 25 min at 4°C.
Results
Kinetics of Binding of ' 257-BSF-2 .
￿
Recombinant BSF-2 was radiolabeled with
'251 as described in Materials and Methods, and radioiodinated BSF-2 was
analyzed by SDS-PAGE . Autoradiography showed only one major band, with an
M, of 21,000 (Fig . 1) . This preparation was used for the analysis of BSF-2-R.
The EBV-transformed B-LCL, CESS, which is known to be responsive to BSF-
2 (16), was used for the initial binding studies . As shown in Fig . 2, the binding
of BSF-2 at 0°C achieved a steady-state level within 150 min . Maximum binding
at 37'C was about one-half that observed at 0'C .Theaddition of0.02% sodium
azide could keep the binding stable at 37'C, but could not increase themaximum970
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FIGURE 3.
￿
Determination of the maximal binding ca-
pacity and specific radioactivity of "'I-BSF-2. (A) 9,300
cpm of '251-BSF-2 was incubated for 150 min with five
different concentrations of CESS cells (up to 5 X 106) in
the presence or absence of 200-fold excess amount of
unlabeledBSF-2. Data (averagesofduplicates) areplotted
as reciprocal specific binding versus reciprocal cells
added. The ordinate intercept of the regression line
B
￿
means the reciprocal counts that would bind at infinite
number of cells (maximal binding capacity). (B) Self-
displacement analysis is performed as described in Mate-
rials andMethods. 9,300cpmof'25I-BSF-2andincreasing
amountsof unlabeled BSF-2 (up to 1.3 ng) or '25I-BSF-2
(up to 80,000 cpm) were incubated with 106 CESS cells.
The mean specific binding of duplicates is plotted as a
bound/free ratio (corrected for maximal binding capac-
ity). Thespecific radioactivity is determined as mentioned
in the text.
.3
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FIGURE 2.
￿
Kinetics of '25I-BSF-2 bind-
ing to CESS cells. 106 CESS cells in 70
pl bindingmedium with 11,000 cpm'251-
BSF-2in thepresence orabsenceof 200-
fold excess unlabeled BSF-2 were incu-
bated for the indicated times at 0°C or
37°C with or without 0.02% sodium
azide. Data represent the mean specific
binding of duplicate samples with the
deviation usually<5%.
binding. In addition, the level ofthe nonspecific binding of 1251-BSF-2 at 37°C
in the presence of 200-fold excess unlabeled BSF-2 was twofold as high as that
at 0°C (data not shown). Therefore, the standard experimental condition of 150
min incubation at 0'C, was used through the study.
Determination of Specific Radioactivity of '251-BSF-2.
￿
To determine how much
ofthe total radiolabeled BSF-2 was bindable to CESS, we used a graphic method
presented previously (14). As briefly described in Materials and Methods, increas-
ing numbers ofCESS cells were incubated with a constant amount of 1251-BSF-2
in a final volume of 70 A,1. Nonspecific binding of 1251-BSF-2 was measured by
the addition of200-fold excess ofunlabeled BSF-2. Fig. 3A shows the regression
line ofthe plot ofreciprocal specific binding versus reciprocal cell number. From
its ordinate intercept, the maximal binding capacity at the infinite cell number-14 -13 -12 -11
logio unlabeled ligand
￿
(mole)
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FIGURE 4. Competition for the binding of '251-BSF-2 by unlabeled BSF-2 and other lym-
phokines to CESS cells. 106 CESS cellsand 5.7
X 10-11 mol of 1251-BSF-2 are incubated in 70
Al binding medium on ice for 150 min with
indicated amount of lymphokines. Data are
mean of duplicatesamples.
was calculated to be 82.6% of the total radioactivity. This means only 17 .4% of
the initial BSF-2 lost its binding ability during radioiodination .
The specific radioactivity of '251-BSF-2 was determined by self-displacement
analysis (14). Details are described in Materials and Methods. Fig. 3 B shows two
regression lines of bound/free ratio versus additional amount of unlabeled BSF-
2 or additional 1251-BSF-2 to a constant set of initial '251-BSF-2 and CESS cells.
The identical slope of the two lines indicates that there was no significant
difference in binding affinity between unlabeled BSF-2 and 1251-BSF-2 to its
receptors. The results indicate that 2 .89 X 10' cpm of 1251-BSF-2 was equivalent
to 0.386 ng of BSF-2 in the meaning of the induction of the same bound/free
ratio of 0.15, thus the calculated specific radioactivity (corrected for the maximal
binding capacity) of 1251-BSF-2 was 6.16 X 1013 cpm/g.
Specificity of 1251-BSF-2 Binding on CESS Cells.
￿
The ability of unlabeled BSF-2
and other cytokines to compete with 1251-BSF-2 for binding sites on CESS cells
is shown in Fig. 4 . Unlabeled BSF-2 inhibited the binding of 1251-BSF-2 in a dose-
dependent manner. As much as 96.5% of the total radioactivity of 1251-BSF-2
bound to CESS without competitor was inhibited by 560-fold excess unlabeled
BSF-2. No significant competition was observed with any other cytokines, such
as IFN-S, IFN-'Y, IL-1#, IL-2, and G-CSF. Previous studies had shown sequence
homology between BSF-2, G-CSF (2), and IFN-0 (17). However, large excess of
G-CSF or IFN-,B could not inhibit the binding of 1251-BSF-2 to CESS, indicating
that BSF-2, IFN-(3, and G-CSF are using different receptors.
Scatchard Plot Analysis of Binding of 1251-BSF-2.
￿
The specific binding of 1251-
BSF-2 to CESS cells as a function of the concentration of 1251-BSF-2 is shown in
Fig. 5A. 1251-BSF-2 bound to CESS in a saturable manner. Analysis of the binding
data by the method of Scatchard (18) revealed only one linear regression line,
indicating that there was a single set of binding sites on CESS (Fig. 5B). The
negative inverse of the regression coefficient gave a dissociation constant of 3 .4
X 10-1° M and the abscissa intercept provided a number of 2,700 binding sites
per cell.
BSF-2-R on Human Cell Lines.
￿
Scatchard analyses were carried out on various
human cell lines and are summarized in Table I. All the analyzed EBV-trans-
formed B cell lines had BSF-2-R with an affinity of 2 .0-4.0 X 10-1° M. The
number of receptors on B-LCL was in the range of 200-2,700 per cell. In
contrast, none of the Burkitt's lymphoma cell lines were found to express anyN
10
x
detectable number ofreceptors. The infection of EBV into EBV- Burkitt's cells
(BL41) or the transfection ofEBNA2 into Burkitt's cells (Louckes) (19) did not
induce any expression ofthe BSF-2-R. The plasma cell lines ARH-77 and U266
displayed 120 and 11,000 receptors per cell, respectively, with affinities of 1.5
X 10-)° and 2.5 X 10-10 M. Four T cell lines tested had no BSF-2-R.
BSF-2-R levels equivalent to CESS cells were detectable on histiocytic leukemia
cell line U937 and promyelocytic leukemia HL60, whereas the receptor number
on astrocytoma U373 and glioblastoma SK-MG-4 was in the low detectable
range. Several other hematopoietic cell lines, such as a non-T, non-B line, KM3
and Reh, did not express any receptors.
BSF-2-R on Normal Lymphocytes.
￿
Normal human T and B cells were purified
from tonsillar mononuclear cells and examined for the expression of BSF-2-R.
Fig. 6 shows specific binding of )25I-BSF-2 to human T cells and its Scatchard
analysis. The results showed that resting T cells expressed BSF-2-R with a
homogeneous affinity. The binding sites per cell were around 300 and the
affinity was 1.4 X 10-)° M. Upon stimulation ofTcells for 3 d with 0.1% PHA
or 0.003% (vol/vol) SAC + 2.5 jug/ml PWM, the level of binding sites remained
constant or were slightly decreased. Activated large T cells displayed fewer
receptors than the smaller ones. These results, summarized in Table II, are in
contrast to the fact that four human T cell lines examined had no significant
number of BSF-2-R (Table I).
In a marked contrast, freshly prepared resting human B cells displayed no
detectable BSF-2-R in the absence ofstimulation (tonsils 1, 2, and 3 in Table II,
lower half). The level of receptor number increased upon activation of B cells
with 0.003% SAC for 1, 2, or 3 d (tonsils 3, 4, and 6). The result obtained with
B cells from the tonsil of individual 3 showed that B cells without any detectable
BSF-2-R before stimulation were induced to express the receptors after 3 d of
culture with SAC, but not with medium alone. Another result with tonsillar B
972
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FIGURE 5. (A) Specific binding of '25I-BSF-2 to EBV-
1 251-BSF2 added (cpm x 1(r4) transformed B cell line CESS. (B) Scatchard plot of the
same data. Theaverage oftheduplicateis shown.TAGA ET AL.
TABLE I
Characteristics ofBSF-2-R on Human Cell Lines
Cells were analyzed by usual binding assay (see Materials and Methods)
and a Scatchard plot. At least four different doses of 121I-BSF-2 were used.
The averages of duplicate determinations were taken for analysis. BL41/95
(27) is an EBV-infected cell line originated from aBurkitt's lymphoma cell line,
BL41 .
* Not significant (<30).
973
cells from individual 4 demonstrated that activated larger B cells on day 1 of
stimulation with SAC expressed ^"600 binding sites per cell with a Kd of 4.2 X
10-'° M, whereas smaller B cells displayed barely detectable number of receptors
(120 receptors), that was similar to the number before stimulation (see also Fig.
7). The result with the tonsil of individual 5 also demonstrated that freshly
prepared large B cells which could be considered in vivo-activated cells, ex-
pressed a small but substantial number of BSF-2-R. Freshly prepared small
resting B cells devoid of BSF-2-R (tonsil 6) were shown to express BSF-2-R after
activation for 2 d with SAC, compared to unstimulated controls. The above
results indicate that BSF-2-R are expressed constitutively on resting T cells, but
are inducible on B cells.
FRCS Analysis ofNormal T Cells and B Cells.
￿
To know the purity of T cells
and B cells prepared from tonsillar mononuclear cells, cells were stained with
fluorescein-conjugated anti-CD3 or anti-CD20 and examined by FACS . The T
Cell line Cell type Sites per
Cell Kd
x10`'° M
CESS EBV-B 2,700 3.4
SKW6-CL4 EBV-B 210 2.0
LCL13 EBV-B 310 4.0
LCL14 EBV-B 410 3.9
BL29 Burkitt's NS*
BL36 Burkitt's NS
BL41 Burkitt's NS
BL41/95 Burkitt's (EBV-infected) NS
Daudi Burkitt's NS
Raji Burkitt's NS
Louckes Burkitt's NS
Louckes/EBNA2 Burkitt's (EBNA2-transfected) NS
ARH-77 Plasma cell 120 1.5
U266 Plasma cell 11,000 2.5
CEM T NS
HSB T NS
Jurkat T NS
OM I T NS
KM3 Non-T non-B NS
Reh Non-T non-B NS
U937 Histiocytoma 2,800 3.3
HL60 Promyelocytic leukemia 3,600 6.4
U373 Astrocytoma 170 1.3
T24 Bladder carcinoma NS
SK-MG-4 Glioblastoma 150 3.9
SK-N-MC Neuroblastoma NS974
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(A) Specific binding of '251-BSF-2 to nor-
mal human T cells. (B) A Scatchard plot of the data
in A. Data representthe mean of theduplicate.
cell fraction used in these studies contained >96% Tcells and the B cell fraction
consisted practically of 100% B cells (data not shown). To demonstrate that BSF-
2-R were expressed mainly on the final maturation stage of B cells, large and
small B cell fractions were stained with anti-Ba and anti-IgD antibodies (20). As
shown in Fig. 8, a large B cell fraction, which expressed BSF-2-R, consisted
mainly of Ba++/IgD- or Ba-/IgD- cells, while large portion of smaller B cell
fraction was IgD'.
Discussion
Cloning ofthe cDNA for BSF-2 (2) enabled us to obtain highly purified BSF-
2 protein generated in E. coli by recombinant DNA technology and has made it
possible to study receptors for BSF-2. We have found that an efficient radioio-
dination of BSF-2 without hindering its binding ability can be achieved with the
use of the Bolton and Hunter reagent. In fact, 83% of the iodinated BSF-2
retained its binding ability, with a specific radioactivity of 6.16 X 10" cpm/g
(Fig. 3). This material has allowed us to analyze the binding properties ofBSF-2
and to detect the presence ofvery low number ofreceptors per cell. In fact, the
identical slope of the two regression lines obtained by the addition ofexcess
1251_
labeled or unlabeled BSF-2 (Fig. 3B) indicates that there was no significant
difference in the binding affinity between labeled and unlabeled BSF-2 to its
receptor. Native BSF-2 purified from a bladder carcinoma line, T24 (21), also
gave a regression line parallel to those in Fig. 3B (data not shown). The molecular
mass shown in Fig. I agrees well with the one of native BSF-2 shown by a
previous study (5). Because the binding property of recombinant BSF-2 does not
seem to be different from native BSF-2, it seems that glycosylation does not play
a critical role in the binding of this cytokine to its receptor.
The kinetic study has demonstrated that binding of 125I-BSF-2 to CESS cellsTAGA ET AL.
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TABLE II
Characteristicsof BSF-2-R on Normal Human T Cells andB Cells
T cellsandB cellswere separated from tonsils of six individuals (numbered 1-6) and
cultured with 0.1% PHA or 2.5,ug/ml PWM + 0.003% SAC (T cells), or 0.003%
SAC or medium alone(B cells) at an initial density of 2 x 10'cells/ml fortheindicated
duration. In some cases, cells were fractionated by size. Scatchard analyses were
performed (see legend of Table I).
* -, unfractionated.
NS, not significant (<30).
4 Freshly prepared small B cells with no detectable number o£ BSF-2-R were cultured
in the absenceof size-fractionation on theday of assay.
was saturated in 150 min at 0'C . In comparison, at 37'C the saturation was
achieved in 60 min but the maximum level of binding was half that found at
0°C. This level was almost the same in the presence of 0.02% sodium azide at
37°C, although the maximum level was more stable than without sodium azide.
Unlike other cytokines (22, 23), the binding property of BSF-2 to its receptor
has a certain peculiarity, in that the level of binding at 0°C is higher than that
at 37'C. In any case, as the nonspecific binding at 0°C was much lower than
that at 37'C, the assay at 0°C provided a suitable condition for the measurement
of BSF-2-R.
We have previously mentioned that the primary structure of BSF-2 has some
homology at the NH2-terminal region with G-CSF (2), and that the organization
of the genomic genes for BSF-2 and G-CSF, both of which had five exons and
four introns, are almost identical (24). Although it has been suggested that some
Cell
type
Tissue
(tonsil)
from
subject:
Cell size* Stimulant Culture
duration
d
Sites per
cell* Kd
X10-10M
Tcells 1 - - 0 290 1.4
1 Large 0.1% PHA 3 220 -
1 Small 0.1% PHA 3 310 1.6
2 - - 0 310 2.0
2 Large 0.1% PHA 3 120 1.6
2 Small 0.1% PHA 3 230 1.5
3 - - 0 350 1.4
4 - - 0 990 2.1
4 - PWM + SAC 3 270 2.8
Bcells 1 - - 0 NS -
2 - - 0 NS -
3 - - 0 NS -
3 - Medium alone 3 NS -2
3 - 0.003% SAC 3 80 3.6
4 - - 0 70 4.5
4 Large 0.003% SAC 1 570 4.2
4 Small 0.003% SAC 1 120 5.0
5 Large - 0 87 4.2
5 Small - 0 NS -
6 Small - 0 NS -
6 Unfractionatedl - 2 NS -
6 Unfractionated4 0.003% SAC 2 230 3.3976
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FIGURE 7 .
￿
(A) Specific binding of ' 211-BSF-2 to nor-
mal B cells . B cells were purified from tonsillar mono-
nuclear cells and cultured with 0.003% SAC for 1 d
and fractionated into large (closed triangles) and small
(closed squares) cells by centrifugation on discontin-
uous gradient of Percoll . Unstimulated nonfraction-
ated B cells (open circles) are also used for binding
assay . (B) Scatchard plots of the same data .
FIGURE 8 .
￿
Two-color FACS analysis of tonsillar B cells stained with anti-Ba and anti-IgD .
Freshly prepared tonsillar B cells (unfractionated, a; large, b; and small, c) were stained with
FITC-anti-IgDand biotinated anti-Ba, anddeveloped with Texas Red-avidin . The expression
of Ba and IgDon cells were analyzed byFACS 440 .
similarity exists between BSF-2 and IFN-# in the COOH-terminal portion (17),
the present study clearly demonstrates that BSF-2 receptors can only bind BSF-
2, not other cytokines such as IFN-# and G-CSF .
The presence of high- and low-affinity receptors for IL-2 and several other
growth factors has been demonstrated (25, 26). From the binding profile and
the Scatchard analysis (Fig . 5), only a single class ofBSF-2 receptors was detected
on CESS cells numbering 2,700 and having a dissociation constant of3.4 X 10- ' °
M . Several cell lines possessed BSF-2-R with similar dissociation constants in the
range of 1 .3-6 .4 X 10- ' ° M (Table I) . Because 1 .2 X 10-9 MBSF-2 was used at
the maximum concentrations in these binding studies, the existence of another
class of receptors with much lower affinity could not be completely excluded .TAGA ET AL.
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The number of receptors was found to vary in the cell lines tested, ranging from
120 to 11,000. Considering the requirement of a very low amount (^-10- " mol)
of BSF-2 for the induction of 50% maximum response of SKW6-CL4 (10,000
cells in 200 j.1 medium), which expressed only 210 receptors, partial occupancy
of low numbers of BSF-2-R expressed on EBV-transformed B cells may be
sufficient to be functional. Therefore, the presence of a large number of
receptors might not be necessary for BSF-2 signal transduction, as observed in
IL-1 stimulation (27).
It is noteworthy that BSF-2-R were expressed on all EBV-transformed B cell
lines examined here but not on any Burkitt's lines (Table I). Two possible
explanations could be given: (a) EBV induces B cells to express BSF-2-R; or (b)
EBV can cause the arrest of B cells at a specific stageof growth or differentiation
in which BSF-2-R could be expressed. The results shown in Table I using two
sets of two different variants of the Burkitt's lines, BL41 or Louckes, showed
that these lines did not express detectable BSF-2-R even after EBV infection or
EBNA2 transfection. EBV-infected BL41/95 has been reported to express lym-
phoblastoid cell associated antigens, whereas BL41 did not (28), and we also
observed BL41/95 making clumps in culture, a typical characteristic of EBV-
infected B cells. This also shows a marked contrast to the expression of a B cell-
specific differentiation antigen, CD23 (FcE receptor), the expression of which
could be inducible by the transfection of EBNA2 (19). This result implies that
the former of the two possible explanations described above is probably not
correct, but further study is required to draw any firm conclusions on the
mechanism of the regulation of BSF-2-R expression.
Not only EBV-transformed B cell lines but also various other human cell lines
expressed BSF-2-R. Among them, it should be noted that human plasma cell
lines, ARH-77 and U266, expressed BSF-2-R, sinceseveral investigators reported
that BSF-2 could function as a plasmacytoma growth factor in a murine system
(7, 29). In a preliminary study, recombinant BSF-2 could induce the proliferation
of myeloma cells freshly prepared from a patient with myeloma (our unpublished
data). Besides B cell lines and plasma cell lines, the histiocytic line U937, the
promyelocytic line HL60, the astrocytoma line U373, and the glioblastoma line
SK-MG-4 displayed BSF-2-R. The finding that BSF-2-R are expressed on cell
lines of different types is in agreement with the wide range of target cells for
BSF-2 (4, 6, 30, 31). Further study should clarify the function of BSF-2 on those
receptor-positive cells. It is interesting to note that in the four cell lines described
above, including an astrocytoma and a glioblastoma line, BSF-2-R were expressed
and BSF-2 itself was inducible after stimulation with IL-1 or TPA (24 and our
unpublished data), whereas a neuroblastoma line neither expressed BSF-2-R nor
produced BSF-2 . These results may suggest the presence of an autocrine mech-
anism in BSF-2-induced differentiation or growth of various cells.
One of the interesting findings was the expression of BSF-2-R on resting T
cells. The situation is similar with BSF-1 (IL-4), which can act on T cells to
induce their proliferation (32). Fewer BSF-2-R were detected on large T cells
compared to small-size T cell fractions (Table II). This might explain the lack in
BSF-2-R on the T cell lines examined, as seen in Table I . The role of BSF-2 on978
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normal T cells is, as yet, unknown. But preliminary studies suggest that BSF-2
could induce IL-2-R expression on certain T cell lines (33).
Recent studies on receptors for cytokines such as IL-1, IL-2, BSF-1, and TNF
(12, 34, 35, 36) demonstrated that cytokines do not have strict target cell
specificity. The present studies show that BSF-2 is no exception. In such a
situation, studies on the regulation of the expression of both cytokines and
receptorsare essential for the elucidationof thebiological role ofthesemolecules.
Normal human B cells usually do not express a significant number of receptors
for BSF-2 before activation (Table II). Upon activation with SAC they were
observed to express 80-570 BSF-2 receptors per cell, with a Kd of 4-5 X 10-'0
M. This smaller number of the receptors may be due to a smaller proportion of
receptor-positive cells among total B cells. Large B cells after 1 d stimulation
with SAC displayed more receptors than smaller ones. As shown in Table II,
even before stimulation in vitro, large B cells freshly prepared from a tonsil
expressed 87 receptors per cell with a similar Kd to other cases, whereas smaller
B cells did not. This means normal B cells can express BSF-2-R when they are
activated in vivo. As reported previously (20), by using anti-Ba (a monoclonal
antibody that recognizes activated B cells) and anti-IgD, tonsillar B cells were
separated into four subpopulations with regard to their activation stage;
Ba-/IgD', Ba+/IgD+, Ba++/IgD-, and Ba-/IgD-. As shown in Fig. 8, more than
half of the freshly prepared large B cells were Ba++/IgD- and most cells were
IgD-. This phenotype of B cell is known to be at the final maturation stage and
ready to produce immunoglobulin (37). These results suggest that normal B cells
become ready to respond to BSF-2 by expressing receptors only when they are
activated. This is in contrast to the BSF-1-R, which are reported to exist on
resting B cells (12, 38, 39). The difference between the mode of the expression
of BSF-1- and BSF-2-R fits the functional difference between BSF-1 and BSF-2
on B cells; the former acts mainly on resting B cells to lead to proliferation in
the presence of anti-IgM, and the latter acts on activated B cells to secrete
immunoglobulin (4, 40). It is notnecessary for normal B cellsto have constitutive
expression ofthe BSF-2-R, but only their transient expression might be sufficient
to drive the cells to a final stage of differentiation .
Summary
B cell stimulatory factor 2 receptors (BSF-2-R) were studied using radioiodi-
nated recombinant BSF-2 with a specific activity of 6.16 X 10'3 cpm/g. Kinetic
studies showed that binding of '25I-BSF-2 to CESS cells reached maximum level
within 150 min at 0°C. There was a single class of receptors with high affinity
(Kd 3.4 X 10-'0 M) on CESS, and the number of receptors was 2,700 per cell.
Binding of '25I-BSF-2 to CESS was competitively inhibited by unlabeled BSF-2
but not by IL-1, IL-2, IFN-,8, IFN--y, and G-CSF, indicating the presence of the
receptorsspecific for BSF-2. EBV-transformed B lymphoblastoid cell lines (CESS,
SKW6-CL4, LCL13, and LCL14) expressed BSF-2-R, whereas Burkitt's lines
did not. EBV or EBNA2 did not induce the expression of the receptors on
Burkitt's cells. The plasma cell lines (ARH-77 and U266) expressed BSF-2-R,
fitting the function of BSF-2 as plasma cell growth factor. Several other cell fines,
the histiocytic line U937, the promyelocytic line HL60, the astrocytoma lineTAGA ET AL.
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U373 and the glioblastoma line SK-MG-4, in which BSF-2 was inducible with
IL-1 or TPA, displayed BSF-2-R with Kd in the range of 1 .3-6.4 X 10-' ° M,
suggesting the autocrine mechanism in BSF-2 function. The four T cell lines
(CEM, HSB, Jurkat, and OM 1) did not express a detectable number ofreceptors,
but normal resting T cells expressed 100-1,000 receptors per cell . BSF-2-R were
not present on normal resting B cells but expressed on activated B cells with a
Kd of 3 .6-5 .0 X 10-'° M, fitting the function of BSF-2, which acts on B cells at
the final maturation stage to induce immunoglobulin production.
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